RecruitingPhase 1NCT07673120

A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses and Multiple Doses of ABBV-313

Sponsor

AbbVie

Enrollment

64 participants

Start Date

Jun 24, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy Volunteers

Summary

The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple doses of ABBV-313 in healthy adult participants.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Inclusion Criteria2

BMI is >= 18.0 to <= 29.9 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.

Exclusion Criteria3

History of any clinically significant sensitivity or allergy to any medication or food.
History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment.
Participant has prior exposure to ABBV-313 within the past 300 days.

Interested in this trial?

Get notified about updates and connect with the research team.